Cullinan Therapeutics Inc (NAS:CGEM)
$ 22.84 0.44 (1.96%) Market Cap: 1.32 Bil Enterprise Value: 861.16 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 36/100

Cullinan Oncology Inc at Barclays Global Healthcare Conference Transcript

Mar 16, 2022 / 07:20PM GMT
Release Date Price: $12.25 (-3.85%)
Unidentified Analyst

Great. Thanks, everyone, for joining us this afternoon. It's my pleasure to introduce our next presenter from Cullinan Oncology, Nadim Ahmed, Chief Executive Officer. With that, I'll pass it to you, Nadim.

Nadim Ahmed
Cullinan Oncology, Inc. - President, CEO & Director

All right. So good afternoon, everyone. First live presentation in 2 years. So thanks for keeping the audience small, easing me back into it. So let me start out by saying a couple of things about Cullinan Oncology. So we're a company that's dedicated to creating new standards of care through a very unique approach to the drug discovery and development process.

Here are disclaimer slides, I will be making forward-looking statements. One thing you'll notice about our company is that we have a very broad and deep pipeline across multiple modalities, different indications, hematology, solid tumors and at various stages of development. And then the other thing I would add, when you look at each program, we have assets that, potentially at least, have the opportunity to be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot